AAAAAA

   
Results: 1-25 | 26-27
Results: 1-25/27
Recommendations and perspectives regarding antiretroviral treatment
Authors: Draenert, R Goebel, FD
Citation: R. Draenert et Fd. Goebel, Recommendations and perspectives regarding antiretroviral treatment, DEUT MED WO, 126(18), 2001, pp. 539-543
Stavudine versus zidovudine and the development of lipodystrophy
Authors: Bogner, JR Vielhauer, V Beckmann, RA Michl, G Wille, L Salzberger, B Goebel, FD
Citation: Jr. Bogner et al., Stavudine versus zidovudine and the development of lipodystrophy, J ACQ IMM D, 27(3), 2001, pp. 237-244
Alterations of apolipoprotein B metabolism in HIV-infected patients with antiretroviral combination therapy
Authors: Schmitz, M Michl, GM Walli, R Bogner, J Bedynek, A Seidel, D Goebel, FD Demant, T
Citation: M. Schmitz et al., Alterations of apolipoprotein B metabolism in HIV-infected patients with antiretroviral combination therapy, J ACQ IMM D, 26(3), 2001, pp. 225-235
Participants in HIV clinical trials in Europe
Authors: Schrooten, W Borchert, M Dreezen, C Baratta, C Smets, E Kosmidis, J Goebel, FD Wilkins, EG Colebunders, R
Citation: W. Schrooten et al., Participants in HIV clinical trials in Europe, INT J STD A, 12(2), 2001, pp. 94-99
Improvement of HAART-associated insulin resistance and dyslipidemia after replacement of protease inhibitors with abacavir
Authors: Walli, R Michl, GM Bogner, JR Goebel, FD
Citation: R. Walli et al., Improvement of HAART-associated insulin resistance and dyslipidemia after replacement of protease inhibitors with abacavir, EUR J MED R, 6(10), 2001, pp. 413-421
Th1/Th2 shift in HIV lymph nodes: No contribution of CD60 cells
Authors: Bogner, JR Walli, R Goebel, FD
Citation: Jr. Bogner et al., Th1/Th2 shift in HIV lymph nodes: No contribution of CD60 cells, INFECTION, 29(1), 2001, pp. 32-36
Phase I/II dose escalation and randomized withdrawal study with add-on azodicarbonamide in patients failing on current antiretroviral therapy
Authors: Goebel, FD Hemmer, R Schmit, JC Bogner, JR de Clercq, E Witvrouw, M Pannecouque, C Valeyev, R Vandevelde, M Margery, H Tassignon, JP
Citation: Fd. Goebel et al., Phase I/II dose escalation and randomized withdrawal study with add-on azodicarbonamide in patients failing on current antiretroviral therapy, AIDS, 15(1), 2001, pp. 33-45
Kaposi's sarcoma-associated herpesvirus serology in Europe and Uganda: Multicentre study with multiple and novel assays
Authors: Schatz, O Monini, P Bugarini, R Neipel, F Schulz, TF Andreoni, M Erb, P Eggers, M Haas, J Butto, S Lukwiya, M Bogner, JR Yaguboglu, S Sheldon, J Sarmati, L Goebel, FD Hintermaier, R Enders, G Regamey, N Wernli, M Sturzl, M Rezza, G Ensoli, B
Citation: O. Schatz et al., Kaposi's sarcoma-associated herpesvirus serology in Europe and Uganda: Multicentre study with multiple and novel assays, J MED VIROL, 65(1), 2001, pp. 123-132
Metabolic complications of antiretroviral treatment of HIV infection
Authors: Goebel, FD Walli, R
Citation: Fd. Goebel et R. Walli, Metabolic complications of antiretroviral treatment of HIV infection, DEUT MED WO, 125(24), 2000, pp. 771-773
Sequence analysis of the HIV-1 protease coding region of 18 HIV-1-infectedpatients prior to HAART and possible implications on HAART
Authors: Gehringer, H Bogner, JR Goebel, FD Nitschko, H von der Helm, K
Citation: H. Gehringer et al., Sequence analysis of the HIV-1 protease coding region of 18 HIV-1-infectedpatients prior to HAART and possible implications on HAART, J CLIN VIRO, 17(2), 2000, pp. 137-141
Increased levels of soluble Fas receptor and Fas ligand in the cerebrospinal fluid of HIV-infected patients
Authors: Sporer, B Koedel, U Goebel, FD Pfister, HW
Citation: B. Sporer et al., Increased levels of soluble Fas receptor and Fas ligand in the cerebrospinal fluid of HIV-infected patients, AIDS RES H, 16(3), 2000, pp. 221-226
Effects of troglitazone on insulin sensitivity in HIV-infected patients with protease inhibitor-associated diabetes mellitus
Authors: Walli, R Michl, GM Muhlbayer, D Brinkmann, L Goebel, FD
Citation: R. Walli et al., Effects of troglitazone on insulin sensitivity in HIV-infected patients with protease inhibitor-associated diabetes mellitus, RES EXP MED, 199(5), 2000, pp. 253-262
AVANTI 2. Randomized, double-blind trial to evaluate the efficacy and safety of zidovudine plus lamivudine versus zidovudine plus lamivudine plus indinavir in HIV-infected antiretroviral-naive patients
Authors: Gartland, M Gerstoft, J Goebel, F Clumeck, N Cooper, DA Gatell, J Gazzard, B Gerstoft, J Goebel, F Lange, J Montaner, J Reiss, P Rozenbaum, W Vella, S Beveridge, A Cooper, DA Duncombe, C Gold, J Haberl, M Clumeck, N Luyts, D Montaner, J Rachlis, A Marina, R Gerstoft, J Wandall, JH Elbrond, B Molina, JM Pialloux, G Rozenbaum, W Beauvais, L Goebel, FD Staszewski, S Bruns, I Hug, M Reiss, P Lange, J Frissen, PHJ van der Ende, ME Bosboom, M Baas, C Milazzo, F Moroni, M Panebianco, R Clotet, B Artigas, JMG Gonzalez-Lahoz, J Leal, M Rodriguez-Lopo, C Gandarias, B Gazzard, B Johnson, M McKinley, S Page, V Watkins, K Sandstrom, E Belsey, E Darbyshire, J Chodakewitz, J Isaacs, R Jonas, L Meibohm, A Coughlan, M Fiddian, P Gartland, M Harrigan, R Larder, B Maguire, M Millard, J Moore, S Patel, K Shortino, D Tisdale, M Vafidis, I Yeo, J
Citation: M. Gartland et al., AVANTI 2. Randomized, double-blind trial to evaluate the efficacy and safety of zidovudine plus lamivudine versus zidovudine plus lamivudine plus indinavir in HIV-infected antiretroviral-naive patients, AIDS, 14(4), 2000, pp. 367-374
Metabolic changes during HIV therapy
Authors: Huster, KM Goebel, FD
Citation: Km. Huster et Fd. Goebel, Metabolic changes during HIV therapy, INTERNIST, 41(11), 2000, pp. 1189
A comparison of exposure groups in the EuroSIDA study: Starting highly active antiretroviral therapy (HAART), response to HAART, and survival
Authors: Mocroft, A Madge, S Johnson, AM Lazzarin, A Clumeck, N Goebel, FD Viard, JP Gatell, J Blaxhult, A Lundgren, JD
Citation: A. Mocroft et al., A comparison of exposure groups in the EuroSIDA study: Starting highly active antiretroviral therapy (HAART), response to HAART, and survival, J ACQ IMM D, 22(4), 1999, pp. 369-378
Neurological manifestations of cytomegalovirus infection in the acquired immunodeficiency syndrome
Authors: Anders, HJ Goebel, FD
Citation: Hj. Anders et Fd. Goebel, Neurological manifestations of cytomegalovirus infection in the acquired immunodeficiency syndrome, INT J STD A, 10(3), 1999, pp. 151-161
Hypocalcaemia in HIV infection and AIDS
Authors: Kuehn, EW Anders, HJ Bogner, JR Obermaier, J Goebel, FD Schlondorff, D
Citation: Ew. Kuehn et al., Hypocalcaemia in HIV infection and AIDS, J INTERN M, 245(1), 1999, pp. 69-73
Acute hypopyon uveitis in a patient with acquired immunodeficiency syndrome treated for systemic Mycobacterium avium complex (MAC) infection with rifabutin
Authors: Schaller, UC Michl, G Goebel, FD Klauss, V
Citation: Uc. Schaller et al., Acute hypopyon uveitis in a patient with acquired immunodeficiency syndrome treated for systemic Mycobacterium avium complex (MAC) infection with rifabutin, OPHTHALMOLO, 96(4), 1999, pp. 267-269
Case 1: Abdominal Burkitt's lymphoma
Authors: Jung, C Gross, M Kronawitter, U Danhauser-Riedl, S Goebel, FD Schlondorff, D
Citation: C. Jung et al., Case 1: Abdominal Burkitt's lymphoma, J CL ONCOL, 17(2), 1999, pp. 726-727
Endothelin-1 is elevated in the cerebrospinal fluid of HIV-infected patients with encephalopathy
Authors: Rolinski, B Heigermoser, A Lederer, E Bogner, JR Loch, O Goebel, FD
Citation: B. Rolinski et al., Endothelin-1 is elevated in the cerebrospinal fluid of HIV-infected patients with encephalopathy, INFECTION, 27(4-5), 1999, pp. 244-247
Hyperlipidemia under treatment with proteinase inhibitors
Authors: Segerer, S Bogner, JR Walli, R Loch, O Goebel, FD
Citation: S. Segerer et al., Hyperlipidemia under treatment with proteinase inhibitors, INFECTION, 27(2), 1999, pp. 77-81
Development of microbial resistance: A global problem - Introduction
Authors: Goebel, FD Adam, D
Citation: Fd. Goebel et D. Adam, Development of microbial resistance: A global problem - Introduction, INFECTION, 27, 1999, pp. S1-S1
Recombinant gp160 as a therapeutic vaccine for HIV-infection: results of alarge randomized, controlled trial
Authors: Goebel, FD Mannhalter, JW Belshe, RB Eibl, MM Grob, PJ de Gruttolae, V Griffiths, PD Erfle, V Kunschak, M Engl, W
Citation: Fd. Goebel et al., Recombinant gp160 as a therapeutic vaccine for HIV-infection: results of alarge randomized, controlled trial, AIDS, 13(12), 1999, pp. 1461-1468
HIV-1 RNA response to antiretroviral treatment in 1280 participants in theDelta Trial: an extended virology study
Authors: Aboulker, JP Babiker, AG Brun-Vezinet, F Darbyshire, JH Flandre, P Gazzard, B Nunn, AJ Goodall, R Aber, V Bragman, K Breckenridge, AM Carbon, C Charreau, I Chene, G Collis, P Cooper, D Dormont, J Fiddian, P Flepp, M Goebel, FD Hooker, M Lange, J Luthy, R Peto, TEA Reiss, P Seligmann, M Stone, AB Thomis, J Vella, S Walckenaer, G Warrell, D Weller, IVD Wilber, R Yeni, P Yeo, J Withnall, R Goudsmit, J Huraux, JM van der Noorda, J Weiss, R Boucher, C Schuurman, R Descamps, D Jeffries, D Tedder, R Weber, J Krzyanowski, C Weverling, G
Citation: Jp. Aboulker et al., HIV-1 RNA response to antiretroviral treatment in 1280 participants in theDelta Trial: an extended virology study, AIDS, 13(1), 1999, pp. 57-65
Analysis of HIV-1 clinical trials: statistical magic?
Authors: Cooper, D Clumeck, N Montaner, J Harrigan, R Gerstoft, J Rozenbaum, W Goebel, FD Reiss, P Lange, J Vella, S Artigas, JMG Gazzard, B
Citation: D. Cooper et al., Analysis of HIV-1 clinical trials: statistical magic?, LANCET, 353(9169), 1999, pp. 2061-2064
Risultati: 1-25 | 26-27